reMYND’s Tau.P301S model is characterized by an age dependent hyperphosporylation and conformational change of Tau which correlates with the behavioural deficit rendering this model ideal for testing Tau-directed therapies.
Hyperphosphorylation in the model have been extensively characterized biochemically and immunohistochemistry using a multitude of phospho-epitope-specific antibodies such as AD2 (pS396/404), AT100 (pT212/S214), pS396, AT8 (pS202/pT205) and the AT180 (pT231) antibodies (figure 1, 2). The inter-mouse onset of the pathology shows little variability and strongly correlates with motor phenotype.
Figure 1: AT100 (phospho Tau pT212/S214) reactive cells in cortex, brainstem and hippocampus. Quantification data available on request.
Figure 2: AT100 measured in cortex and brainstem using biochemistry (left) and rotarod performance (right). Additional quantification data (epitopes or age series) available on request.
A proprietary data package on the Tau.P301S model is available on request. Please contact Bart Roucourt, CRO Manager, for any inquiries.